Broadfoot Jill Marie — SEC Form 4 filings
SEC reporting owner CIK 1305178. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-01-09 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $8,950 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 4,402 shares, $8,948 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 5,000 shares @ $1.79 ($8,950) in aTYR PHARMA INC, filed 2024-06-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| aTYR PHARMA INC (ATYR) | Chief Financial Officer | 7 | 1 leg · 5,000 sh · $8,950 | 3 legs · 4,402 sh · $8,948 | 9 |
| TALPHERA, INC. (TLPH) | Director | 3 | — | — | 6 |
| Cue Biopharma, Inc. (CUE) | Director | 2 | — | — | 2 |
Form 4 filings — Broadfoot Jill Marie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | TALPHERA, INC. (TLPH) | Grant/award (A): 5,100 @ $0 · Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | aTYR PHARMA INC (ATYR) | Option exercise (M): 3,750 · Sale (S): 1,558 @ $0.98 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 412,500 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 24,400 (derivative) @ $0 | EDGAR |
| 2025-10-24 | 4 | TALPHERA, INC. (TLPH) | Grant/award (A): 4,267 @ $0 · Grant/award (A): 25,600 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 48,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | aTYR PHARMA INC (ATYR) | Option exercise (M): 3,750 · Sale (S): 1,254 @ $3.78 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | TALPHERA, INC. (TLPH) | Grant/award (A): 2,174 @ $0 · Grant/award (A): 13,044 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | aTYR PHARMA INC (LIFE) | Purchase (P): 5,000 @ $1.79 | EDGAR |
| 2024-02-06 | 4 | aTYR PHARMA INC (LIFE) | Option exercise (M): 3,750 · Sale (S): 1,590 @ $1.69 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | aTYR PHARMA INC (LIFE) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1305178 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →